


IN THE CLAIMS

Please cancel claim 4 without prejudice to applicants' right to pursue the cancelled subject matter in a later filed divisional or continuation application.

Claims 2, 3, and 17 to 20 were canceled in applicants' April 29, 2003 Amendment filed in response to the December 31, 2002 Office Action.

Please amend claim 6 as follows (deletions are shown in strikethrough).

1. (Previously Amended) A compound of the formula 1




or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:

m is an integer from 0 to 3;

p is an integer from 0 to 4;

each R¹ and R² is independently selected from H and C₁-C₆ alkyl;

R³ is selected from



wherein the foregoing R³ groups are optionally substituted by 1 to 3 R⁸ groups;

R⁴ is $-(\text{CR}^{16}\text{R}^{17})_m\text{-C}\equiv\text{C-(CR}^{16}\text{R}^{17})_l\text{R}^9$, $-(\text{CR}^{16}\text{R}^{17})_m\text{-C}\equiv\text{C-(CR}^{16}\text{R}^{17})_l\text{-R}^9$, $-(\text{CR}^{16}\text{R}^{17})_m\text{-C}\equiv\text{C-(CR}^{16}\text{R}^{17})_k\text{R}^{13}$, $-(\text{CR}^{16}\text{R}^{17})_m\text{-C}\equiv\text{C-(CR}^{16}\text{R}^{17})_k\text{R}^{13}$, or $-(\text{CR}^{16}\text{R}^{17})_l\text{R}^9$, wherein the